New HIV pill for kids pulled before start

NCT ID NCT06139796

Terminated Disease control Sponsor: PENTA Foundation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to test a new solid tablet combining two HIV drugs (darunavir and ritonavir) for children aged 3 and older weighing 10-25 kg. The goal was to find the right dose and check safety and acceptability. However, the trial was withdrawn before any participants were enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Darunavir/Ritonavir (DRV/r) 120/20 mg fixed-dose combination tablet
What this could lead to: If successful, this could provide a more convenient, child-friendly tablet option for treating HIV in children.
What could go wrong: The trial was withdrawn before enrolling any participants, so no data will be collected. The formulation may still need further testing in future studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

Baylor College of Medicine Children's Foundation

Kampala, Uganda, 72052, Uganda
Centre Hospitalier National d'Enfants Albert Royer

Dakar, Senegal, 25755, Senegal
Centre Mère et Enfant de la Fondation Chantal Biya

Yaoundé, Cameroon, 1, Cameroon
Joint Clinical Research Centre (JCRC)

Kampala, Uganda
University of Zimbabwe Clinical Research Centre (UZCRC)

Harare, Zimbabwe, Zimbabwe

More trials for these conditions

Other studies related to the condition(s) this trial covers.